240 related articles for article (PubMed ID: 15222776)
1. Dose response and atypical antipsychotics in schizophrenia.
Kinon BJ; Ahl J; Stauffer VL; Hill AL; Buckley PF
CNS Drugs; 2004; 18(9):597-616. PubMed ID: 15222776
[TBL] [Abstract][Full Text] [Related]
2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
3. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
4. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P; Ratner S; Laor N; Weizman A
Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy.
Markowitz JS; Brown CS; Moore TR
Ann Pharmacother; 1999 Jan; 33(1):73-85. PubMed ID: 9972387
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
9. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs.
Brown CS; Markowitz JS; Moore TR; Parker NG
Ann Pharmacother; 1999 Feb; 33(2):210-7. PubMed ID: 10084417
[TBL] [Abstract][Full Text] [Related]
11. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Stahl SM; Grady MM
Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.
Hugenholtz GW; Heerdink ER; Stolker JJ; Meijer WE; Egberts AC; Nolen WA
J Clin Psychiatry; 2006 Jun; 67(6):897-903. PubMed ID: 16848649
[TBL] [Abstract][Full Text] [Related]
14. Selection of atypical antipsychotics for the management of schizophrenia.
Sprague DA; Loewen PS; Raymond CB
Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
[TBL] [Abstract][Full Text] [Related]
15. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
Mauri MC; Volonteri LS; Colasanti A; Fiorentini A; De Gaspari IF; Bareggi SR
Clin Pharmacokinet; 2007; 46(5):359-88. PubMed ID: 17465637
[TBL] [Abstract][Full Text] [Related]
17. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
Weiden P; Aquila R; Standard J
J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.
Gentile S
Drug Saf; 2006; 29(4):303-19. PubMed ID: 16569080
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
